An analysis of supply chain strategies in the regenerative medicine industry - Implications for future development

Chih Wei Teng, Lucy Foley, Peter Joseph O'Neill, Christian Hicks

Research output: Contribution to journalArticleResearchpeer-review

Abstract

The pharmaceutical, biotechnology and life sciences industry was worth approximately US 1 trillion in 2010, of which 73.2 was attributed to pharmaceuticals, 25 to biotechnology and the remainder to life sciences. Regenerative medicines, which use live cells to cure previously incurable diseases, are a small, but growing sector of the life sciences industry. Product development here is long, the industry highly regulated and scaling up from lab to volume oriented dispersed production has many challenges. In contrast to most manufacturing environments, it is not possible to change manufacturing processes or supply chains ad hoc, as the entire supply process is specified as part of regulatory approval. It is therefore prudent to plan for the integration of production processes and supply chains during development, as the cost ramifications will seal the success or failure of a therapy at start up. This paper presents a taxonomy, which decomposes regenerative medicine into exemplar cellular therapies that then enables the characterization of their supply chain strategies and structures. Using a case study methodology, we explore the supply chains of five cellular therapies to provide insight into how regenerative medicine supply chains could be configured and managed to get cell therapies to more markets faster, and within an acceptable cost regime.
Original languageEnglish
Pages (from-to)211 - 225
Number of pages15
JournalInternational Journal of Production Economics
Volume149
DOIs
Publication statusPublished - 2014

Cite this

@article{34c35be49f5f48f59ed9e16672278c6b,
title = "An analysis of supply chain strategies in the regenerative medicine industry - Implications for future development",
abstract = "The pharmaceutical, biotechnology and life sciences industry was worth approximately US 1 trillion in 2010, of which 73.2 was attributed to pharmaceuticals, 25 to biotechnology and the remainder to life sciences. Regenerative medicines, which use live cells to cure previously incurable diseases, are a small, but growing sector of the life sciences industry. Product development here is long, the industry highly regulated and scaling up from lab to volume oriented dispersed production has many challenges. In contrast to most manufacturing environments, it is not possible to change manufacturing processes or supply chains ad hoc, as the entire supply process is specified as part of regulatory approval. It is therefore prudent to plan for the integration of production processes and supply chains during development, as the cost ramifications will seal the success or failure of a therapy at start up. This paper presents a taxonomy, which decomposes regenerative medicine into exemplar cellular therapies that then enables the characterization of their supply chain strategies and structures. Using a case study methodology, we explore the supply chains of five cellular therapies to provide insight into how regenerative medicine supply chains could be configured and managed to get cell therapies to more markets faster, and within an acceptable cost regime.",
author = "Teng, {Chih Wei} and Lucy Foley and O'Neill, {Peter Joseph} and Christian Hicks",
year = "2014",
doi = "10.1016/j.ijpe.2013.06.006",
language = "English",
volume = "149",
pages = "211 -- 225",
journal = "International Journal of Production Economics",
issn = "0925-5273",
publisher = "Elsevier",

}

An analysis of supply chain strategies in the regenerative medicine industry - Implications for future development. / Teng, Chih Wei; Foley, Lucy; O'Neill, Peter Joseph; Hicks, Christian.

In: International Journal of Production Economics, Vol. 149, 2014, p. 211 - 225.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - An analysis of supply chain strategies in the regenerative medicine industry - Implications for future development

AU - Teng, Chih Wei

AU - Foley, Lucy

AU - O'Neill, Peter Joseph

AU - Hicks, Christian

PY - 2014

Y1 - 2014

N2 - The pharmaceutical, biotechnology and life sciences industry was worth approximately US 1 trillion in 2010, of which 73.2 was attributed to pharmaceuticals, 25 to biotechnology and the remainder to life sciences. Regenerative medicines, which use live cells to cure previously incurable diseases, are a small, but growing sector of the life sciences industry. Product development here is long, the industry highly regulated and scaling up from lab to volume oriented dispersed production has many challenges. In contrast to most manufacturing environments, it is not possible to change manufacturing processes or supply chains ad hoc, as the entire supply process is specified as part of regulatory approval. It is therefore prudent to plan for the integration of production processes and supply chains during development, as the cost ramifications will seal the success or failure of a therapy at start up. This paper presents a taxonomy, which decomposes regenerative medicine into exemplar cellular therapies that then enables the characterization of their supply chain strategies and structures. Using a case study methodology, we explore the supply chains of five cellular therapies to provide insight into how regenerative medicine supply chains could be configured and managed to get cell therapies to more markets faster, and within an acceptable cost regime.

AB - The pharmaceutical, biotechnology and life sciences industry was worth approximately US 1 trillion in 2010, of which 73.2 was attributed to pharmaceuticals, 25 to biotechnology and the remainder to life sciences. Regenerative medicines, which use live cells to cure previously incurable diseases, are a small, but growing sector of the life sciences industry. Product development here is long, the industry highly regulated and scaling up from lab to volume oriented dispersed production has many challenges. In contrast to most manufacturing environments, it is not possible to change manufacturing processes or supply chains ad hoc, as the entire supply process is specified as part of regulatory approval. It is therefore prudent to plan for the integration of production processes and supply chains during development, as the cost ramifications will seal the success or failure of a therapy at start up. This paper presents a taxonomy, which decomposes regenerative medicine into exemplar cellular therapies that then enables the characterization of their supply chain strategies and structures. Using a case study methodology, we explore the supply chains of five cellular therapies to provide insight into how regenerative medicine supply chains could be configured and managed to get cell therapies to more markets faster, and within an acceptable cost regime.

U2 - 10.1016/j.ijpe.2013.06.006

DO - 10.1016/j.ijpe.2013.06.006

M3 - Article

VL - 149

SP - 211

EP - 225

JO - International Journal of Production Economics

JF - International Journal of Production Economics

SN - 0925-5273

ER -